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We thank Perry for raising the interesting difference between
research trials where both patients and staff are blinded to
whether the tablet is really a statin and everyday practice where
patients and doctors know whether a statin is being taken.1 2 In
the blinded trials, there are indeed reports of symptoms, but (in
the published data) these are equivalent between statin and
placebo. In everyday practice, there are reports of symptoms
but no blinded comparator group.
While in some cases symptoms might be a pharmacological
effect that cannot be evaded, the blinded randomised data
suggest that in other cases it might be a non-pharmacological
(nocebo) effect. In routine practice patients have no way to find
out for themselves which is the case for them individually.
We are delighted to report that the British Heart Foundation is
supporting a patient centred randomised controlled trial with
multiple blinded segments for each patient (statin, placebo, and
no treatment). We expect this to allow patients to judge for
themselves where symptoms are coming from—the statin or
being on any tablet (even placebo).
We invite any UK based doctors with patients who have stopped
statins because of symptoms to look at the SAMSON website
(http://www.preventingheartdisease.org/) and get in touch with
us.
Together we may be able to move closer to providing what our
patients most need—a simple, scientifically valid, and
personalised answer to this vexing question.
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